Unit-II/Part-B

Diuretics

PRESENTED BY;MR. SAMARPAN MISHRA (ASSISTANT PROFESSOR)
SPECIALIZATION:- PHARMACEUTICAL CHEMISTRY


Diuretics

- I. Diuretics are medications that increase the excretion of water and electrolytes (mainly sodium and chloride) from the body through urine.
- II. They act on the kidneys to promote diuresis (urine production).
- III. Diuretics are primarily used in the treatment of hypertension, heart failure, edema, and certain kidney disorders.


Classification of Diuretics

- 1. Carbonic anhydrase inhibitors:- Acetazolamide*, Methazolamide, Dichlorphenamide.
- 2. Thiazides:- Chlorthiazide*, Hydrochlorothiazide, Hydroflumethiazide, Cyclothiazide.
- 3. Loop diuretics:- Furosemide*, Bumetanide, Ethacrynic acid.
- 4. Potassium sparing Diuretics:- Spironolactone, Triamterene, Amiloride.
- 5. Osmotic Diuretics: Mannitol.

Methazolamide



Dichlorphenamide




Amiloride


Hydrochlorothiazide



Hydroflumethiazide




Cyclothiazide



Mannitol

Bumetanide

Ethacrynic acid



Spironolactone

Triamterene

MOA of Each Category of Diuretics

| 1. | Carbonic | Anhy | vdrase | Inhibitors |
|----|-----------|---------|----------|-------------------|
| т. | Cai built | T FILLS | y un asc | |

| ☐ These | e diuretics | s inhibit the | e enzyme | carbonic | anhydrase, | which p | olays a r | ole in t | ne reabso | rption c | of bicarbo | nate (I | HCO3-) | and h | ydrogen | ions | (H+) : | in the |
|---------|-------------|---------------|-------------|----------|------------|---------|-----------|----------|-----------|----------|------------|---------|--------|-------|---------|------|--------|--------|
| proxii | mal conve | oluted tubu | le of the r | nephron. | | | | | | | | | | | | | | |

- ☐ By inhibiting this enzyme, they increase the excretion of sodium (Na+), bicarbonate, and water, making the urine more alkaline
- Examples include acetazolamide and methazolamide.

2. Thiazide Diuretics:

- ☐ Thiazides work by inhibiting the sodium-chloride symporter in the distal convoluted tubule, preventing the reabsorption of sodium and chloride ions.
- ☐ This leads to increased excretion of sodium, chloride, and water, as well as potassium.
- □ Examples include hydrochlorothiazide, chlorthalidone, and indapamide.

3. Loop Diuretics:


- ☐ Also known as high-ceiling diuretics, they act on the thick ascending limb of the loop of Henle.
- ☐ They inhibit the sodium-potassium-chloride cotransporter, preventing the reabsorption of these ions and increasing water excretion.
- □ Examples include furosemide, bumetanide, and ethacrynic acid.

4. Potassium-Sparing Diuretics:


- ☐ These diuretics act on the collecting duct, either by blocking aldosterone receptors (aldosterone antagonists) or by directly inhibiting sodium channels.
- ☐ They promote sodium excretion and potassium retention, hence the name "potassium-sparing".
- □ Examples include spironolactone (aldosterone antagonist) and amiloride (sodium channel blocker).

5. Osmotic Diuretics:


- ☐ These agents are filtered by the glomerulus but are not reabsorbed by the tubules.
- ☐ They create an osmotic gradient that draws water into the tubules, increasing urine volume.
- □ Examples include mannitol, urea, and glycerol.



Synthesis of Furosemide




Synthesis of Chlorthiazide



Chlorothiazide

SAR of Thazides



General Structure

| Position | Modification | Effect on Activity | | | | | |
|--|--|---|--|--|--|--|--|
| 2-Position | Introduction of an electron-withdrawing group (e.g., Cl, CF ₃) | Essential for diuretic activity. Enhances potency. | | | | | |
| 3-Position | Sulfonamide (-SO ₂ NH ₂) group is essential | Necessary for interaction with Na ⁺ /Cl ⁻ symporter | | | | | |
| 3,4-Dihydro derivative (saturation of double bond) | Increases potency (e.g., hydrochlorothiazide) | More potent than unsaturated analogs. | | | | | |
| 6-Position | Substitution with Cl or CF3 increases lipophilicity | Improves membrane permeability and potency. | | | | | |
| 7-Position | Unsubstituted or alkyl groups tolerated | Minor effect on activity. | | | | | |
| Substitution at 1-N | Not favorable | Reduces activity | | | | | |
| Modification of sulfonamide group | N ⁴ -substitution can improve potency or alter kinetics | Some derivatives show increased duration of action | | | | | |

THANK YOU